Top Industry Leaders in the Gastritis Treatment Market
Latest Gastritis Treatment Companies Updates:
AstraZeneca PLC (UK): Launched its Nexium 40 mg chewable tablets in the US in July 2023, offering a convenient and patient-friendly option for managing acid reflux and esophagitis associated with gastritis.
Takeda Pharmaceutical Company Limited (Japan): Received FDA approval for its Vonoprazan (TAK-438) for treating erosive esophagitis, expanding its portfolio of drugs targeting upper gastrointestinal conditions like gastritis.
Microbiotix, Inc. (US): Presented successful preliminary clinical trial results for its investigational live bacterial therapeutic, MBX8866, in treating H. pylori infection, a major cause of gastritis.
Reddy's Laboratories Ltd. (India): Partnered with US-based biopharmaceutical company, Ocugen, Inc., to develop and commercialize biosimilars of PPIs, increasing access to affordable treatment options in emerging markets.
Bio-Rad Laboratories, Inc. (US): Showcased its advanced diagnostic tests for H. pylori and other gastric disorders at a recent medical conference, highlighting the importance of accurate diagnosis for effective gastritis treatment.
List of Gastritis Treatment Key companies in the market:
- Abbott Laboratories
- AstraZeneca PLC
- Novartis AG
- Microbiotix, Inc
- Reddy’s Laboratories
- Lupin Ltd
- Perrigo Pharmaceutical
- Cipla Inc.
- Pfizer Inc.
